Stay Informed

Get email alerts when new recalls match your interests.

Recall data is updated hourly from official government sources. Very recent recalls may not yet appear. About our data sources

About

We make U.S. recall data searchable and accessible for consumers and businesses.

Site

FAQ
Browse by State
Statistics
Recall Classifications
About
Enterprise API

Legal

Privacy Policy
Terms of Service
Report Incorrect Info

Official Sources

FDA Recalls ↗
USDA FSIS ↗
CPSC Recalls ↗
NHTSA Recalls ↗

RSS Feed

Home
/
Brands
/
Teva Pharmaceuticals USA

Teva Pharmaceuticals USA Recalls

All product recalls associated with Teva Pharmaceuticals USA.

Get alerts for this brand

Recall Summary

Total Recalls

265

Past Year

Class I (Serious)

Most Recent

Nov 2025

Data from FDA, USDA, CPSC, and NHTSA public records. Recall counts vary by company size, industry, and reporting practices. Always check official sources for current information.

Showing 221–240 of 265 recalls

Fluoxetine 20mg Capsules (Teva) – Odor Contamination (2014)

Chemical Contamination: Recall due to a customer complaint trend regarding capsule odor.

Class IIModerate

FDAFeb 12, 2014Nationwide• Teva Pharmaceuticals USA

Fluoxetine 10mg Capsules (Teva) – Odor Contamination (2014)

Chemical Contamination: Recall due to a customer complaint trend regarding capsule odor.

Class IIModerate

FDAFeb 12, 2014Nationwide• Teva Pharmaceuticals USA

QVAR Inhalation Aerosol (Teva) – Impurity Specification (2014)

Failed Impurity/Degradation Specification; for 17-BMP at the 9 and 18 month stability time point

Class III

1...10 111213 14

Page 12 of 14Next

Low

FDAFeb 11, 2014Nationwide• Teva Pharmaceuticals USA

Hydroxyzine Pamoate Capsules (Teva) – CGMP Manufacturing Deviation (2014)

CGMP Deviations: Hydroxyzine Pamoate Capsules, USP, 25 mg were manufactured using an unapproved material: API was incorrectly released for use in manufacturing.

Class IIModerate

FDAJan 24, 2014Nationwide• Teva Pharmaceuticals USA

Hydroxyzine Pamoate Capsules (Teva) – CGMP Manufacturing Deviation (2014)

CGMP Deviations: Hydroxyzine Pamoate Capsules, USP, 100 mg were manufactured using an unapproved material: API was incorrectly released for use in manufacturing.

Class IIModerate

FDAJan 24, 2014Nationwide• Teva Pharmaceuticals USA

Ethambutol Tablets (Teva) – CGMP Manufacturing Deviation (2014)

CGMP Deviations: Ethambutol Hydrochloride Tablets, USP, 400 mg were manufactured using unapproved material: the incorrect gelatin excipient than specified in the product formulation.

Class IIModerate

FDAJan 24, 2014Nationwide• Teva Pharmaceuticals USA

Dextroamphetamine Tablets (Teva) – CGMP Manufacturing Deviation (2014)

CGMP Deviations: Dextroamphetamine Saccharate, Amphetamine Asparate, Dextroamphetamine Sulfate and Amphetamine Sulfate Tablets, CII, 10 mg were manufactured using unapproved material: the finished product was not properly quarantined as rejected due to inadequate cleaning of equipment.

Class IIModerate

FDAJan 24, 2014Nationwide• Teva Pharmaceuticals USA

Hydralazine HCL 25mg Tablets (Teva) – Impurity Risk (2013)

Failed Impurities/Degradation Specifications:There is a potential for the tablets to be out of specification for impurities throughout shelf life.

Class IIModerate

FDADec 18, 2013Nationwide• Teva Pharmaceuticals USA

Hydralazine HCL 50mg Tablets (Teva) – Impurity Risk (2013)

Failed Impurities/Degradation Specifications:There is a potential for the tablets to be out of specification for impurities throughout shelf life.

Class IIModerate

FDADec 18, 2013Nationwide• Teva Pharmaceuticals USA

Qnasl Nasal Aerosol (Teva) – Defective Delivery System (2013)

Defective Delivery System: There is a potential for some units in certain lots of Qnasl Nasal Aerosol 80 mcg metered spray to have clogged stem valves.

Class IIILow

FDADec 4, 2013Nationwide• Teva Pharmaceuticals USA

Niacin Extended Release Tablets (Teva) – Tablet Defect (2013)

Failed Tablet/Capsule Specifications: There is a potential for broken tablets.

Class IIModerate

FDANov 26, 2013Nationwide• Teva Pharmaceuticals USA

Fluconazole Suspension (Teva) – Preservative Issue (2013)

Failed Stability Specifications: this product is below specification for preservative content.

Class IIILow

FDANov 14, 2013Nationwide• Teva Pharmaceuticals USA, Inc.

Valacyclovir Tablets (Teva) – Foreign Tablet Contamination (2013)

Presence of Foreign Tablets/Capsules: Potential of Pravastatin tablet fragments in bottles of Valacyclovir 1 gm Tablets.

Class IIModerate

FDANov 8, 2013Nationwide• Teva Pharmaceuticals USA, Inc.

Copaxone (Teva) – Particulate Matter Risk (2013)

Presence of Particulate Matter: A foreign particle found in a pre-filled syringe was reported through a consumer complaint about a pre-filled syringe.

Class IIModerate

FDAOct 24, 2013Nationwide• Teva Pharmaceuticals USA

Daunorubicin Hydrochloride Injection (Teva) – drug precipitation (2013)

Presence of Precipitate; precipitation of drug product

Class IIModerate

FDAOct 11, 2013Nationwide• Teva Pharmaceuticals USA

CARBOplatin Injection (Teva) – Endotoxin Validation Failure (2013)

Lack of Assurance of Sterility: The required reduction of endotoxin was not met during the annual revalidation of the vial washer.

Class IIModerate

FDAAug 13, 2013Nationwide• Teva Pharmaceuticals USA, Inc.

Propranolol Tablets (Teva) – tablet specification (2013)

Failed Tablet/Capsule Specification: Teva is recalling certain lots of Propanolol HCl Tablets, 10 mg due to the potential of some tablets not conforming to weight specification.

Class IIModerate

FDAAug 6, 2013Nationwide• Teva Pharmaceuticals USA, Inc.

Terazosin Hydrochloride Capsules (Teva) – Strength Mislabeling (2013)

Labeling -label error on declared strength: unopened, sealed bottle of Terazosin Hydrochloride (HCl) 10mg Capsules contained Terazosin HCl 5 mg Capsules

Class IIModerate

FDAJul 23, 2013Nationwide• Teva Pharmaceuticals USA, Inc.

Methylphenidate Extended-Release (Teva) – dissolution failure (2013)

Failed Dissolution Specifications: Product is being recalled due to out of specification dissolution results obtained during routine stability testing.

Class IIModerate

FDAJun 18, 2013Nationwide• Teva Pharmaceuticals USA, Inc.

Amoxicillin Oral Suspension (Teva) – Orange Discoloration (2013)

Discoloration: This recall is being carried out due to an orange to brown discolored Amoxicillin powder on the inner foil seal of the bottles. This is an expansion of RES 65050.

Class IIILow

FDAJun 18, 2013Nationwide• Teva Pharmaceuticals USA, Inc.